Primary Breast Tumors with Mesenchymal Morphology
Overview Mesenchymal tumors of the breast are rare. Few epithelial tumors also have mesenchymal components. It is crucial to identify these as per histogenesis. This can be facilitated by markers of epithelial–mesenchymal transition (EMT).
Objectives The aim of this study was to categorize the breast lesions with mesenchymal morphology and to study EMT on immunohistochemistry (IHC).
Materials and Methods This is a retrospective study of 5-year duration from January 2015 to December 2019. Inclusion criteria: all breast lesions showing mesenchymal/nonepithelial morphology, complete or partial, on histology. Exclusion criteria: Mammary carcinomas without any mesenchymal/nonepithelial morphology, fibroadenomas, and lymphomas. Demographics, clinical, gross examination, histology, and IHC findings of selected cases were reviewed and recorded. Three additional markers p53, E-cadherin, and β-catenin were performed.
Statistical Analysis Used Frequency calculation for each variable (IHC).
Results Thirteen (2.5%) out of total 510 breast specimens showed mesenchymal histology. Of these, five (38.5%) were metaplastic breast carcinomas (MBC), four (31%) were phyllodes tumor (PT), and one (7.7%) case each of malignant peripheral nerve sheath tumor, primary stromal sarcoma of breast, pseudoangiomatous stromal hyperplasia, and myofibroblastoma. Loss of E-cadherin was seen in 4/5 (80%) MBCs and was retained in ductal component of PTs. p53 was not expressed in any of the tumors except 3/5 (60%) MBCs. β-Catenin was aberrant in all MBCs.
Conclusions Primary breast tumors with mesenchymal morphology present a spectrum ranging from benign mesenchymal, fibroepithelial neoplasms to malignant tumors of mesenchymal and epithelial origin. Loss of E-cadherin, expression of p53, and aberrant expression of β-catenin are suggestive of EMT and molecular heterogeneity of MBCs.
Artikel online veröffentlicht:
09. Juli 2021
© 2021. The Indian Association of Laboratory Physicians. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
- 1 O’Donnell ME, McCavert M, Carson J, Mullan FJ, Whiteside MW, Garstin WI. Non-epithelial malignancies and metastatic tumours of the breast. Ulster Med J 2009; 78 (02) 105-112
- 2 Young Jr JL, Ward KC, Wingo PA, Howe HL. The incidence of malignant non-carcinomas of the female breast. Cancer Causes Control 2004; 15 (03) 313-319
- 3 Goldblum JR, Lazar AJ, Schnitt SJ, Tan PH. Mesenchymal tumours of the Breast. In: WHO Classification of Tumours Editorial Board. Breast Tumours. 5th edition. Lyon, France: International Agency for Research on Cancer 2019: 187-230
- 4 Schwartz TL, Mogal H, Papageorgiou C, Veerapong J, Hsueh EC. Metaplastic breast cancer: histologic characteristics, prognostic factors and systemic treatment strategies. Exp Hematol Oncol 2013; 2 (01) 31
- 5 Lacroix-Triki M, Geyer FC, Lambros MB. et al β-catenin/Wnt signalling pathway in fibromatosis, metaplastic carcinomas and phyllodes tumours of the breast. Mod Pathol 2010; 23 (11) 1438-1448
- 6 Ng CKY, Piscuoglio S, Geyer FC. et al The landscape of somatic genetic alterations in metaplastic breast carcinomas. Clin Cancer Res 2017; 23 (14) 3859-3870
- 7 Lee SK, Bae SY, Lee JH. et al Distinguishing low-risk luminal a breast cancer subtypes with ki-67 and p53 is more predictive of long-term survival. PLoS One 2015; 10 (08) e0124658
- 8 van der Kooy K, Rookus MA, Peterse HL, van Leeuwen FE. p53 protein overexpression in relation to risk factors for breast cancer. Am J Epidemiol 1996; 144 (10) 924-933
- 9 Adem C, Reynolds C, Ingle JN, Nascimento AG. Primary breast sarcoma: clinicopathologic series from the Mayo Clinic and review of the literature. Br J Cancer 2004; 91 (02) 237-241
- 10 Pollard SG, Marks PV, Temple LN, Thompson HH. Breast sarcoma. A clinicopathologic review of 25 cases. Cancer 1990; 66 (05) 941-944
- 11 Weiss SW, Goldblum JR. Malignant tumors of the peripheral nerves. In: Strauss M, Grey L, eds. Enzinger and Weiss’s Soft Tissue Tumors. 4th edition. St. Louis: Mosby Inc 2001: 1209-1264
- 12 Ducatman BS, Scheithauer BW, Piepgras DG, Reiman HM, Ilstrup DM. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer 1986; 57 (10) 2006-2021
- 13 Dhingra KK, Mandal S, Roy S, Khurana N. Malignant peripheral nerve sheath tumor of the breast: case report. World J Surg Oncol 2007; 5: 142
- 14 Kumar S, Sharma J, Ralli M, Singh G, Kalyan S, Sen R. Primary stromal sarcoma of breast: a rare entity. Iran J Pathol 2016; 11 (05) 469-473
- 15 Tse G, Koo JS, Thike AA. Phyllodes tumours. In: WHO Classification of Tumours Editorial Board. Breast Tumours. 5th edition. Lyon, France: International Agency for Research on Cancer 2019: 172-176
- 16 Gatalica Z, Finkelstein S, Lucio E. et al p53 protein expression and gene mutation in phyllodes tumors of the breast. Pathol Res Pract 2001; 197 (03) 183-187
- 17 Hoda SA, Brogi E, Koerner FC, Rosen PP. Rosen’s Breast Pathology. 4th edition. New York: Lippincott, Williams & Wilkins 2014: 547-599
- 18 Zhang Y, Toy KA, Kleer CG. Metaplastic breast carcinomas are enriched in markers of tumor-initiating cells and epithelial to mesenchymal transition. Mod Pathol 2012; 25 (02) 178-184
- 19 Geyer FC, Weigelt B, Natrajan R. et al Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas. J Pathol 2010; 220 (05) 562-573
- 20 Lee WA. Prognostic significance of abnormal β-catenin expression in breast carcinoma. J Korean Med Sci 2005; 39 (02) 114-119